Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Placebo Effect01:54

The Placebo Effect

The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Bipolar Disorder01:30

Bipolar Disorder

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential effect of specific gr/gr deletion subtypes on spermatogenesis in the Chinese Han population.

International journal of andrology·2009
Same author

Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC.

Biologicals : journal of the International Association of Biological Standardization·2009
Same author

Modular "plug-and-play" capsules for multi-capsule environment in the gastrointestinal tract.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2009
Same author

Non-virus-mediated transfer of siRNAs against Runx2 and Smad4 inhibit heterotopic ossification in rats.

Gene therapy·2009
Same author

Identification of messenger RNA substrates for mouse T-STAR.

Biochemistry. Biokhimiia·2009
Same author

Could changes in arterioles impede the perivascular drainage of interstitial fluid from the cerebral white matter in leukoaraiosis?

Neuropathology and applied neurobiology·2009
Same journal

International challenges and public policy issues.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in China.

Developments in biological standardization·2000
Same journal

ICH activities on biotech topics.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in the European Union.

Developments in biological standardization·2000
Same journal

Standardisation and licensing of combination vaccines based on DTP.

Developments in biological standardization·2000
Same journal

Control of foot-and-mouth disease by vaccination.

Developments in biological standardization·2000
See all related articles

Related Experiment Video

Updated: Jun 30, 2026

A Protocol for Transcranial Photobiomodulation Therapy in Mice
13:07

A Protocol for Transcranial Photobiomodulation Therapy in Mice

Published on: November 18, 2018

Betaseron

L Lin1

  • 1Chiron Corporation, Emeryville, CA 94608-2916, USA.

Developments in Biological Standardization
|January 16, 1999
PubMed
Summary
This summary is machine-generated.

Betaseron, a genetically engineered beta-interferon, offers enhanced stability for treating multiple sclerosis. Its production and characterization in E. coli ensure consistent therapeutic efficacy.

More Related Videos

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
05:19

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

High-Throughput Behavioral Aging and Lifespan Assays Using the Lifespan Machine
08:53

High-Throughput Behavioral Aging and Lifespan Assays Using the Lifespan Machine

Published on: January 26, 2024

Related Experiment Videos

Last Updated: Jun 30, 2026

A Protocol for Transcranial Photobiomodulation Therapy in Mice
13:07

A Protocol for Transcranial Photobiomodulation Therapy in Mice

Published on: November 18, 2018

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
05:19

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

High-Throughput Behavioral Aging and Lifespan Assays Using the Lifespan Machine
08:53

High-Throughput Behavioral Aging and Lifespan Assays Using the Lifespan Machine

Published on: January 26, 2024

Area of Science:

  • Biotechnology
  • Protein Engineering
  • Immunology

Background:

  • Betaseron is a recombinant analogue of human beta-interferon, engineered with a serine-cysteine substitution at position 17 for improved storage stability.
  • It is a non-glycosylated polypeptide produced in E. coli, exhibiting biological activities similar to native interferon-beta.

Purpose of the Study:

  • To detail the manufacturing process and comprehensive characterization of Betaseron.
  • To validate the quality and consistency of Betaseron for therapeutic use, particularly in multiple sclerosis treatment.

Main Methods:

  • Synthesis in E. coli, isolation as inclusion bodies, solubilization, reduction, purification via organic extraction and chromatography.
  • Analytical verification including amino/carboxy-terminal sequencing, peptide mapping, amino acid analysis, SDS-PAGE, and reversed-phase HPLC.
  • Characterization of minor product-related species and confirmation of disulfide bond formation.

Main Results:

  • The primary amino acid sequence of Betaseron was confirmed to match the DNA prediction.
  • Manufacturing processes ensure the formation of a key intramolecular disulfide bond.
  • Extensive analytical methods confirm high purity and consistent product quality.

Conclusions:

  • Betaseron's comprehensive characterization and established manufacturing provide a robust foundation for its therapeutic application.
  • Redundant release testing could potentially be streamlined for this well-characterized protein, optimizing production efficiency.